Fig. 3
From: ATRX immunostaining predicts IDH and H3F3A status in gliomas
Kaplan-Meier survival plots. a Diffuse gliomas of WHO G7rade II separated by ATRX status (n = 130); median: 2141 days in ATRX loss group vs. 1175 days in ATRX retention group. b Astrocytoma WHO grade II and III grouped (n = 176), tumors harbouring ATRX loss (n = 96) had a significantly better outcome compared to tumors with ATRX retention (n = 80) (median: 1952 vs. 818 days, p < 0.0001) c Astrocytic, oligodendroglial and mixed tumors without 1p/19q codeletion (n = 230) show a significant better outcome when accompanied with ATRX loss than with ATRX retention (median ATRX loss 1769 days vs. ATRX retention 1127 days, p = 0.0046)